Moses Makunje
Director of Finance/CFO at NUVATION BIO INC.
Net worth: 27 803 $ as of 30/04/2024
Moses Makunje active positions
| Companies | Position | Start | End |
|---|---|---|---|
| NUVATION BIO INC. | Comptroller/Controller/Auditor | 27/11/2023 | - |
| Director of Finance/CFO | 27/11/2023 | - | |
| Corporate Officer/Principal | 01/07/2020 | 27/11/2023 |
Career history of Moses Makunje
Former positions of Moses Makunje
| Companies | Position | Start | End |
|---|---|---|---|
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01/03/2019 | 01/07/2020 |
Statistics
International
| 2 | |
| United States | 2 |
Operational
| Comptroller/Controller/Auditor | 2 |
| Director of Finance/CFO | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
| Nuvation Bio, Inc. | |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
- Stock Market
- Insiders
- Moses Makunje
- Experience
